SHARE THIS POST

December 20, 2016 – GW Pharmaceuticals (NASDAQ:GWPH) filed an information statement on Form 6-K this week, reporting that Dr. Stephen Wright, its Chief Medical Officer and Director, exercised options to acquire 281,052 of the Company’s ordinary shares, 0.1 pence each, which were subsequently converted into 23,421 American Depository Shares and sold at $116.59 per ADS.

Dr. Wright retains a beneficial interest in vested options to acquire 321,938 ordinary shares (equivalent to 26,828 ADSs), 4,359 ordinary shares (equivalent to 362 ADSs) and unvested options over an additional 449,264 ordinary shares (equivalent to 37,439 ADSs).

Separately, Terra Tech (OTC:TRTC) filed an 8-K announcing that has raised $5,000,000 through the sale of a 12% Senior Convertible Promissory Note, due June 16, 2018. The principal and interest is convertible into shares of Common Stock at the election of the Note Holder at the lower of $0.27 or 85% of the lowest daily volume weighted average price (“VWAP”) of the Common Stock in the 15 trading days prior to the conversion date. Additional terms including ratchet, adjustments in the case of default, a forced conversion feature, etc. are discussed in the docs filed with the 8-K.

And 22nd Century Group (NYSE MKT:XXII) announced in an 8-K that it has entered into a Research Funding Agreement with The Rector and Visitors of the University of Virginia and an Exclusive License Agreement with the University of Virginia Patent Foundation.

Under the Research Funding Agreement, 22nd Century Group will collaborate with the University and provide about $1.1 million in funding to the University over a 3-year period for activities relating to the creation of unique industrial hemp plants with optimized traits for commercial uses and medical study.

Under the Executive License Agreement, the Company has been granted exclusive rights to commercialize all results of the collaboration with the University in consideration of the payment of royalties by the Company to UVA LVG from the net sales received by the Company from its commercialization of the results of the collaboration.